Watchlist Price Alert

XOMA Corporation (XOMA)

NASDAQ: XOMA · Real-Time Price · USD

27.45

0.00 (0.00%)

At close: Jun 26, 2025, 3:59 PM

27.32

-0.47%

After-hours: Jun 26, 2025, 04:00 PM EDT

0.00% (1D)

Bid	26.5
Market Cap	328.49M
Revenue (ttm)	36.54M
Net Income (ttm)	-2.86M
EPS (ttm)	-0.73
PE Ratio (ttm)	-37.6
Forward PE	85.36
Analyst	Buy

Ask	29.68
Volume	10,123
Avg. Volume (20D)	40,796
Open	27.49
Previous Close	27.45
Day's Range	26.69 - 27.76
52-Week Range	18.35 - 35.00
Beta	0.94

About XOMA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XOMA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for XOMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

XOMA Corporation is scheduled to release its earnings on Aug 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

-3.05%

XOMA Royalty shares are trading higher after the c... Unlock content with Pro Subscription

News

2 days ago · zacks.com

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?

XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng...

1 month ago · zacks.com

XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates

XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago.

2 months ago · accessnewswire.com

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-clas...

2 months ago · seekingalpha.com

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

XOMA aggregates future biotech royalties and milestone rights for stable, diversified revenue streams. However, I believe its preferred shares (under tickers XOMAO and XOMAP) offer attractive yields w...